Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal auto-M2-BFs for Organic Brain Syndrome
NCT02957123Phase 2Completed
- Sponsor
- Russian Academy of Sciences
- Start
- Mar 2016
- Primary completion
- Sep 2020
- Modality
- Inhalation Devices, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of M2-BFs, sponsored by Russian Academy of Sciences. Primary endpoint: Number of Patients With Severe Adverse Events and Adverse Reactions at 6 months. Started Mar 2016; status: completed.
02
Drugs
M2-BFs
Beyond the preview
Go deeper on NCT02957123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957123.